[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].

Autor:	Gaultier De Saint Basile H; Hôpital Cochin, service d'oncologie médicale, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France., Poisson C; Hôpital Cochin, service d'oncologie médicale, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France., Arrondeau J; Hôpital Cochin, service d'oncologie médicale, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France; Hôpital Cochin, CERTIM, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France; Université Paris Descartes, 12, rue de l'École-de-médecine, 75006 Paris, France. Electronic address: jennifer.arrondeau@aphp.fr., Boudou-Rouquette P; Hôpital Cochin, service d'oncologie médicale, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France; Hôpital Cochin, CERTIM, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France., Goldwasser F; Hôpital Cochin, service d'oncologie médicale, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France; Hôpital Cochin, CERTIM, 123, boulevard de Port-Royal, 75679 Paris cedex 14, France; Université Paris Descartes, 12, rue de l'École-de-médecine, 75006 Paris, France., Tartour E; Hôpital européen Georges-Pompidou, laboratoire d'immunologie biologique, 20, rue Leblanc, 75015 Paris, France; Équipe 10 « immunothérapies et traitements anti-angiogéniques en oncologie », faculté de médecine Paris Descartes, Inserm U970, 12, rue de l'école de médecine, 75006 Paris, France., De Guillebon E; Hôpital européen Georges-Pompidou, service d'oncologie médicale, 20, rue Leblanc, 75015 Paris, France; Équipe 10 « immunothérapies et traitements anti-angiogéniques en oncologie », faculté de médecine Paris Descartes, Inserm U970, 12, rue de l'école de médecine, 75006 Paris, France.
Jazyk:	francouzština
Zdroj:	Bulletin du cancer [Bull Cancer] 2018 Dec; Vol. 105 (12), pp. 1202-1208. Date of Electronic Publication: 2018 Nov 22.
DOI:	10.1016/j.bulcan.2018.10.004
Abstrakt:	Physiological aging causes qualitative or quantitative immune system decline, also called immunosenescence. Older people with cancer are often ineligible for chemotherapy. The new immunotherapies (with PD1, PDL1 and CTLA4 checkpoint inhibitors) have proven their effectiveness in many tumor types regardless of age and are often better tolerated than chemotherapy. In the older population, the subgroup data from the different pivotal studies show fairly reassuring efficacy and safety data, despite the frequent lack of power given the small population included. There remains, however, some doubt that age may be a risk factor for hyperprogression. Studies focusing on older subjects and dedicated meta-analysis seem necessary to obtain more accurate data. (Copyright © 2018.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu